Yellowstone Bio develops off‑the‑shelf therapeutics that target frequently expressed, shared antigens on cancer cells, focusing on acute myeloid leukaemia and other high‑risk hematologic malignancies. Using a proprietary antigen discovery and validation platform, the company creates bispecific antibodies and T‑cell engagers designed for selective tumor killing while minimizing off‑target effects. Its pipeline is intended for licensing to pharma and biotech partners seeking ready‑to‑use, antigen‑targeted drug candidates.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers, including acute myeloid leukaemia (AML), express antigens that are common across patients but lack effective therapeutic strategies, limiting treatment options and patient outcomes.
Solution
Yellowstone Bio is developing a new class of therapeutics that target frequently expressed, shared antigens on cancer cells. Leveraging proprietary discovery platforms and deep expertise in haematology, the company identifies and validates these common antigens for drug development. Their approach focuses on creating modalities—such as bispecific antibodies or T‑cell engagers—that can recognize and eliminate cancer cells bearing these antigens while sparing normal tissue. By concentrating on antigens that are broadly present across patient populations, Yellowstone aims to produce off‑the‑shelf treatments that can be rapidly deployed in clinical settings. The pipeline is built on rigorous pre‑clinical validation and is positioned to address unmet needs in AML and other high‑risk malignancies.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking licensed antigen‑targeted therapeutic candidates, as well as clinical research organizations conducting trials in AML and other hematologic cancers.
Features
- Proprietary antigen discovery pipeline that screens for widely expressed tumor-associated antigens across multiple cancer types
- Target validation using patient‑derived samples and advanced molecular profiling to ensure relevance in AML and related myeloid disorders
- Development of bispecific antibody and T‑cell engager formats designed for high affinity and selective tumor cell killing
- Integrated pre‑clinical safety assessment platform to evaluate on‑target/off‑tumor risk early in the development cycle
- Scalable manufacturing strategy aimed at producing off‑the‑shelf therapeutic candidates for rapid clinical rollout